Gram-negative Bacterial Infections Clinical Trial
Official title:
Piperacillin as a Part of Antibiotic Streamlining in the Intensive Care Unit
The proposed endpoints of the study would be: comparative use of piperacillin versus broader spectrum agents (e.g., piperacillin/tazobactam, etc.) [measured as defined daily doses per 1000 patient days]; physician acceptance of piperacillin as part of a streamlining program [measured as successful occurrences of the use of piperacillin as streamlining therapy]; changes in susceptibility patterns of broad spectrum antibiotics [measured as % Gram negative bacilli susceptible to each of the commonly used broad spectrum antibiotics]; and outcome of patients treated with streamlined therapy.
The following variables will be followed: time and location of positive cultures, underlying diseases and severity of illness, recent immunomodulative therapies, physical exam findings, laboratory and radiographical data, antimicrobial usage, microbiological data and resistance patterns, choice of antibiotics once organism is identified, suspected source of infection, bacteriological outcomes, laboratory results, demographic information, medications, clinical outcome, gender, height, weight, ethnicity, and past medical history. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00723502 -
Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients
|
Phase 2 | |
Suspended |
NCT00563134 -
A Randomised Trial on the Saftely and Efficacy of GR270774 in the Treatment of Gram-negative Sepsis in Adult
|
N/A | |
Active, not recruiting |
NCT05171257 -
Quantifying Gram-negative Resistance to Empiric Therapy in the Intensive Care Unit
|
||
Completed |
NCT03160040 -
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Minocin® (Minocycline) for Infections Caused by Gram-negative Bacteria in a Real World Setting
|
||
Completed |
NCT02962934 -
An Observational Pharmacokinetic Sudy of Ceftolozane-Tazobactam in Intensive Care Unit in Patients With and Without CRRT
|
||
Not yet recruiting |
NCT06135350 -
Clinical Trial to Study the Efficacy and Safety of Fluorothiazinone (N.F. Gamaleya NRCEM) in Prophylaxis of Nosocomial Bacterial Infections With Participation of Patients on MV
|
Phase 2 | |
Enrolling by invitation |
NCT04055922 -
Comparison of Solid Organ Transplant
|
||
Completed |
NCT00490477 -
The Effects of Polymyxin-B Protects on Sepsis Induced Kidney Dysfunction: a Randomized Clinical Trial
|
Phase 3 | |
Recruiting |
NCT04861922 -
Unfractioned Heparin for Treatment of Sepsis Caused by Abdominal Infection
|
Phase 3 | |
Completed |
NCT01732250 -
Multicenter Open-label Randomized Controlled Trial (RCT) to Compare Colistin Alone Versus Colistin Plus Meropenem
|
Phase 4 | |
Completed |
NCT00406198 -
Impact of Continuous Venovenous Haemofiltration on Organ Failure During the Early Phase of Severe Sepsis
|
Phase 4 | |
Recruiting |
NCT06086626 -
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants
|
Phase 2 | |
Withdrawn |
NCT04785924 -
Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections
|
Phase 4 | |
Completed |
NCT02285075 -
Temocillin Pharmacokinetic in Hemodialysis
|
Phase 4 | |
Completed |
NCT03182504 -
A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT04917380 -
The Clinical Character,Risk and Prognosis of Post-neurosurgical Intracranial Infection With Different Pathogens.
|
||
Terminated |
NCT05210387 -
Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections
|
N/A | |
Completed |
NCT03397914 -
Effect of Different Colistin Doses on Clinical Outcome of Pediatric Cancer Patients With Gram Negative Infections
|
Phase 4 | |
Completed |
NCT02088840 -
Survey of Severe Infections by Gram Negative Bacteria in Patients Submitted to Stem Cell Transplant
|
||
Recruiting |
NCT01600768 -
Evaluation of Extended Intravenous of Beta-lactams in the Treatment of Serious Gram-negative Infections in Critically Ill Patients
|
N/A |